CTOs on the Move

Luca Technologies

www.lucatechnologies.com

 
Luca Technologies, Inc. engages in the development of long-term biotechnology-driven solutions to the natural gas market in the United States.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Hendricks Regional Health

Hendricks Regional Health is a non-profit, multi-specialty healthcare organization caring for communities in the Western and Central suburban area of Indianapolis since 1962, with a full-service hospital in Danville and medical buildings in Avon, Bainbridge, Brownsburg, Plainfield and Lizton. In December 2017, we will be opening our second hospital to serve the growing needs of the Brownsburg area.

Sound Technology Inc

Sound Technology Inc is a State College, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GreeneCountyHealthCare

Greene County Health Care (GCHC) Inc. is a non-profit organization that provides high quality, integrated, and affordable health care to residents of Greene, Pitt, and Pamlico counties in eastern North Carolina, with a focus on the uninsured, underinsu...

Abbott House

The Abbott Union Free School District provides programs especially designed for children with special needs.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.